Keywords:
Genital / Reproductive system female, Oncology, Pelvis, MR, Ultrasound, MR-Diffusion/Perfusion, Imaging sequences, Contrast agent-intravenous, Staging, Cancer, Image registration, Neoplasia
Authors:
B. Olimov1, F. Kossov2, O. Kirillova2, M. Khulamkhanova2, V. Panov2, I. E. Tyurin2, N. Levchenko3, B. Dolgushin2; 1Moskow /RU, 2Moscow/RU, 3Moscow /RU
DOI:
10.1594/ecr2018/C-0188
Methods and materials
A total of 52 patients (22-87 years,
mean – 58 years; 19 patients with benign/borderline OT (BOT),
including endometriomas and cystic teratomas and 33 cases with malignant OT (MOT) were examined by MRI (Magnetom Espree® 1.5T and Magnetom Skyra® 3.0T (Siemens,
Germany) before surgery and/or combined treatment.
For all of the patients were performed,
routine spin-echo T1WI and T2WI,
DWI (b value = 50,
1000,
1500,
2100,
2500) with ADC maps and DCE-MRI after gadobutrol (Gadovist®,
Bayer,
Germany) i.v.
injection (3 ml/s) at standard dose 0.1 mmol/kg by Medrad® Spectris Solaris® EP (Bayer,
Germany).
We analysed the difference of signal intensity (SI) on DWI with different b values (1000-2500) and the mean ADC values for the solid and cyst components of the OT.
Also we parameterized DCE-MRI using mathematical models that included the enhancement amplitude (EA),
the time interval of half rising (THR) and the maximal slope (MS).
Myometrium was an internal reference tissue for DCE-MRI parameters ratios calculation (EAr,
THRr and MSr,
respectively).
The initial area under the curve for first 60 seconds after gadobutrol injection ratio (IAUC60ratio) were also determined.